Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer vaccines - Marker Therapeutics Inc

Drug Profile

Research programme: cancer vaccines - Marker Therapeutics Inc

Alternative Names: AdhTAP; AdhTAP(OS-1); HER2/Neu T-cell vaccine - Marker Therapeutics Inc; TPIV 120; TPIV 130

Latest Information Update: 11 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TapImmune
  • Developer Marker Therapeutics Inc
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Mar 2019 Marker Therapeutics has patent protection and pending patents for PolyStartTM technology in USA
  • 17 Oct 2018 TapImmune merged with Marker Therapeutics and changed its name to Marker Therapeutics Inc., while its subsidiary changed the name to Marker Cell Therapy
  • 04 Dec 2017 Preclinical development is ongoing in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top